Since we uncovered that depleted RBMS1 reduces PD-L1 level, thereby promoting anti-tumor T-cell immunity, we chose CTLA4 blockade for the combination therapy with RBMS1 depletion in the mouse 4T1 engraftment model. The gene discussed is RBMS1; the disease is neoplasm.